Freedland SJ - Search Results

1

Prognostic utility of cell cycle progression score in men with prostate cancer after primary external beam radiation therapy.

Freedland SJ, Gerber L, Reid J, Welbourn W, Tikishvili E, Park J, Younus A, Gutin A, Sangale Z, Lanchbury JS, Salama JK, Stone S. Freedland SJ, et al. Int J Radiat Oncol Biol Phys. 2013 Aug 1;86(5):848-53. doi: 10.1016/j.ijrobp.2013.04.043. Epub 2013 Jun 5. Int J Radiat Oncol Biol Phys. 2013. PMID: 23755923 Free PMC article.

2

Obesity, serum prostate specific antigen and prostate size: implications for prostate cancer detection.

Freedland SJ, Platz EA, Presti JC Jr, Aronson WJ, Amling CL, Kane CJ, Terris MK. Freedland SJ, et al. J Urol. 2006 Feb;175(2):500-4; discussion 504. doi: 10.1016/S0022-5347(05)00162-X. J Urol. 2006. PMID: 16406980

3

Prostate-specific antigen: update 2006.

Freedland SJ, Partin AW. Freedland SJ, et al. Urology. 2006 Mar;67(3):458-60. doi: 10.1016/j.urology.2005.12.026. Epub 2006 Feb 28. Urology. 2006. PMID: 16504254 Review. No abstract available.

4

Delay of radical prostatectomy and risk of biochemical progression in men with low risk prostate cancer.

Freedland SJ, Kane CJ, Amling CL, Aronson WJ, Presti JC Jr, Terris MK; SEARCH Database Study Group. Freedland SJ, et al. J Urol. 2006 Apr;175(4):1298-302; discussion 1302-3. doi: 10.1016/S0022-5347(05)00646-4. J Urol. 2006. PMID: 16515984

5

Update on outcomes research databases in prostate cancer 2006.

Freedland SJ, Krupski TL, Moul JW. Freedland SJ, et al. Curr Opin Urol. 2006 May;16(3):168-72. doi: 10.1097/01.mou.0000193394.62221.e9. Curr Opin Urol. 2006. PMID: 16679854 Review.

6

Is biopsy Gleason score independently associated with biochemical progression following radical prostatectomy after adjusting for pathological Gleason score?

Fitzsimons NJ, Presti JC Jr, Kane CJ, Terris MK, Aronson WJ, Amling CL, Freedland SJ. Fitzsimons NJ, et al. Among authors: freedland sj. J Urol. 2006 Dec;176(6 Pt 1):2453-8; discussion 2458. doi: 10.1016/j.juro.2006.08.014. J Urol. 2006. PMID: 17085127

7

Radical prostatectomy for clinical stage T3a disease.

Freedland SJ, Partin AW, Humphreys EB, Mangold LA, Walsh PC. Freedland SJ, et al. Cancer. 2007 Apr 1;109(7):1273-8. doi: 10.1002/cncr.22544. Cancer. 2007. PMID: 17315165 Free article.

8

Upgrading and downgrading of prostate needle biopsy specimens: risk factors and clinical implications.

Freedland SJ, Kane CJ, Amling CL, Aronson WJ, Terris MK, Presti JC Jr; SEARCH Database Study Group. Freedland SJ, et al. Urology. 2007 Mar;69(3):495-9. doi: 10.1016/j.urology.2006.10.036. Urology. 2007. PMID: 17382152 Free PMC article.

9

Death in patients with recurrent prostate cancer after radical prostatectomy: prostate-specific antigen doubling time subgroups and their associated contributions to all-cause mortality.

Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, Dorey FJ, Walsh PC, Partin AW. Freedland SJ, et al. J Clin Oncol. 2007 May 1;25(13):1765-71. doi: 10.1200/JCO.2006.08.0572. J Clin Oncol. 2007. PMID: 17470867

10

Obesity and prostate cancer: making sense out of apparently conflicting data.

Freedland SJ, Platz EA. Freedland SJ, et al. Epidemiol Rev. 2007;29:88-97. doi: 10.1093/epirev/mxm006. Epub 2007 May 3. Epidemiol Rev. 2007. PMID: 17478439 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

777 results

Search Page

Filters